Table 2. Patient characteristics of the CLL1 study cohort.
| Total | Progranulin low (≤79.2 ng/ml) | Progranulin high (>79.2 ng/ml) | p | ||
| Age | N | 163 | 82 | 81 | 0.967 |
| mean ± SD | 59.94±8.22 | 60.21±7.95 | 59.68±8.53 | ||
| median (range) | 61 (35–75) | 60.5 (35–75) | 62 (37–75) | ||
| Sex | Male | 96 (58.9%) | 49 (51.0%) | 47 (49.0%) | 0.628 |
| female | 62 (38.0%) | 29 (46.8%) | 33 (53.2%) | ||
| missing | 5 (3.1%) | ||||
| Study arm * | low risk | 138 (84.7%) | 76 (55.1%) | 62 (44.9%) | 0.008 |
| high risk | 24 (14.7%) | 6 (25%) | 18 (75%) | ||
| missing | 1(0.6%) | ||||
| IGHV | Unmutated | 42 (25.8%) | 11 (26.2%) | 31 (73.8%) | <0.001 |
| mutated | 121 (74.2%) | 71 (58.7%) | 50 (41.3%) | ||
| FISH risk group ** | low risk | 153 (93.9%) | 81 (52.9%) | 72 (47.1%) | 0.009 |
| high risk | 10 (6.1%) | 1 (10%) | 9 (90%) | ||
| β2-microglobulin | N | 163 | 82 (49.3%) | 81 (50.7%) | 0.001 |
| mean ± SD | 1.67±0.59 | 1.52±0.40 | 1.81±0.70 | ||
| median (range) | 1.53 (0.90–6.2) | 1.5 (0.9–3.1) | 1.68 (0.95–6.2) | ||
| Thymidine kinase | N | 163 | 82 | 81 | 0.002 |
| mean ± SD | 7.49±6.05 | 5.97±3.68 | 9.02±7.47 | ||
| median (range) | 5.5 (2.0–34.1) | 5.15 (2.0–20.4) | 6.5 (2.0–34.1) | ||
| Leucocytes | N | 133 (82.6%) | 68 (51.1%) | 65 (48.9%) | <0.001 |
| mean ± SD | 27.6±23.7 | 20.8±9.4 | 34.8±31.1 | ||
| median (range) | 21.6 (4.7–184.0) | 18.4 (6.3–66.0) | 26.4 (4.7–184.0) | ||
| Lymphocyte doubling time (LDT) | <12 months | 27 (16.6%) | 11 (40.7%) | 16 (59.3%) | 0.299 |
| ≥12 months | 134 (82.2%) | 70 (52.2%) | 64 (47.8%) | ||
| missing | 2 (1.2%) | ||||
| LDH blood level | N | 146 (89.6%) | 72 (49.3%) | 74 (50.7%) | 0.006 |
| mean ± SD | 195.1±71.8 | 178.5±46.3 | 211.3±87.3 | ||
| median (range) | 178 (82–732) | 169.5 (82–332) | 183 (94–732) | ||
| Therapy | therapy | 55 (33.7%) | 17 (30.9%) | 38 (69.1%) | <0.001 |
| no therapy | 108 (66.3%) | 65 (60.2%) | 43 (39.8%) | ||
| Survival | Dead | 20 (12.3%) | 3 (15%) | 17(85%) | 0.001 |
| alive | 143 (87.7%) | 79 (55.2%) | 64 (44.8%) |
*
high risk, as defined by the following: serum thymidine kinase level>7.0 U/L, β2-microglobulin>3.5 mg/l level, presence of non-nodular bone marrow infiltration, LDT<12 months; low risk: none of the criteria listed for high risk disease.
**
For definition of cytogenetic risk see legend to Table 1. All risk parameters except LDT were determined at the time of study entry.